The current targeted clinical treatment of melanoma consists of two key therapeutic areas, vemurafenib against BRAF mutant cells, and anti-immune checkpoint therapies, both of which display very visible clinical benefits [13,15,16]. The gene discussed is BRAF; the disease is melanoma.